Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as IONIS-AGT-LRx
ISIS 757456 · 2 trials · 2 indications
The baseline for plasma AGT was defined as the average of all values prior to the first dose of study drug.
| Arm | Type | Description |
|---|---|---|
| Placebo | PLACEBO_COMPARATOR | Participants received ISIS 757456-matching placebo, subcutaneous (SC) injection, once-weekly for 8 weeks and an additional loading dose on Day 3. |
| ISIS 757456 | EXPERIMENTAL | Participants received ISIS 757456 80 mg, SC injection, once-weekly for 8 weeks and an additional loading dose on Day 3. |
| ISIS 757456 80 mg | EXPERIMENTAL | ISIS 757456 80 mg injected SC once weekly for up to 6 weeks and an additional loading dose of 80 mg on Day 3. |
| Name | Type | Description |
|---|---|---|
| Placebo | DRUG | ISIS 757456-matching placebo solution administered as SC injection. |
| ISIS 757456 | DRUG | ISIS 757456 administered as SC injection. |
Inclusion criteria: * Males or females aged 18-75 inclusive and weighing ≥ 50 kilograms (kg) at the time of informed consent * Females must be non-pregnant and non-lactating, and either surgically sterile or post-menopausal * Males must be surgically sterile or, abstinent or, if engaged in sexual r...
Top 9 of 16 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AstraZeneca PLC | AZN | 5 | PHASE3 | Baxdrostat |
| Eli Lilly and Company | LLY | 4 | PHASE3 | Orforglipron, Clazakizumab |
| Alnylam Pharmaceuticals, Inc | ALNY | 2 | PHASE3 | Zilebesiran, ALN-AGT01 RVR |
| Mineralys Therapeutics, Inc. | MLYS | 1 | PHASE3 | lorundrostat |
| United Therapeutics Corporation | UTHR | 1 | PHASE3 | Ralinepag |
| Novartis AG Sponsored ADR | NVS | 3 | PHASE2 | QCZ484, HJB647 |
| Vanda Pharmaceuticals Inc. | VNDA | 1 | PHASE2 | iloperidone |
| Opus Genetics, Inc. | IRD | 1 | PHASE1 | OPGx-BEST1 |
| CRISPR Therapeutics AG | CRSP | 1 | PHASE1 | CTX340 |
ISIS 757456, also known as IONIS-AGT-LRx, is an investigational antisense inhibitor being studied for the treatment of hypertension, including mild hypertension. It is administered subcutaneously and is currently in Phase 2 clinical development for these cardiovascular conditions.
ISIS 757456 is being developed by Ionis Pharmaceuticals, Inc., a biopharmaceutical company traded on NASDAQ under the ticker symbol IONS. The company is conducting clinical trials to evaluate the safety, tolerability, and efficacy of this investigational drug in patients with hypertension.
ISIS 757456 is in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still being studied in clinical trials. Two Phase 2 trials have been completed, but the drug remains under investigation for hypertension.
ISIS 757456 has been studied in two completed Phase 2 clinical trials. NCT03714776 assessed the drug in participants with mild hypertension, while NCT04083222 evaluated it in patients with hypertension. Both trials were conducted in the United States and enrolled adult participants.
Yes, ISIS 757456 is also known as IONIS-AGT-LRx. The drug is an antisense inhibitor developed by Ionis Pharmaceuticals for the treatment of hypertension. Clinical trial records refer to the drug by both names, with IONIS-AGT-LRx being the more recent designation.